HF3054 (Legislative Session 94 (2025-2026))
Prescription drug transparency provisions modified.
Related bill: SF3294
AI Generated Summary
Purpose of the Bill
The bill focuses on enhancing prescription drug transparency by modifying existing Minnesota laws. It aims to provide clearer insights into drug pricing, specifically related to the 340B Drug Pricing Program, and to ensure accountability from pharmaceutical manufacturers regarding drug prices and price increases.
Main Provisions
- 340B Program Reporting: Entities participating in the federal 340B Drug Pricing Program are required to submit detailed annual reports to the Minnesota health commissioner. These reports must include aggregated acquisition costs, payment amounts, and the number of units dispensed, broken down by payer type.
- Enforcement and Compliance: Entities failing to comply with reporting requirements may face daily fines. Extensions or exemptions can be granted upon demonstrating good cause.
- Legislative Reports: The health commissioner must annually submit reports to the legislature summarizing the collected data, with an emphasis on 340B entities whose revenues significantly impact overall 340B financial activities in Minnesota.
Significant Changes to Existing Law
- Revised Definitions and Reporting for Prescription Drugs: Expands and clarifies definitions around prescription drugs, biosimilars, and related terms. It requires manufacturers to report price increases when certain thresholds are exceeded.
- Public Posting Requirements: The commissioner must make non-confidential prescription drug price information available to the public online. Certain drug price data is to be excluded from public posting if determined to be non-public or trade secret.
- Prescription Drugs of Public Interest: Introduces a mechanism for identifying and publicly listing drugs of significant public interest, subject to specific criteria and limitations on the number designated.
Relevant Terms
- 340B Drug Pricing Program
- Prescription drug transparency
- Biosimilars
- Brand name drugs
- Generic drugs
- Drug price increases
- Drug manufacturer reporting
- Health commissioner
- Public posting of drug prices
- Substantial public interest drugs
Bill text versions
- Introduction PDF file
Actions
| Date | Chamber | Where | Type | Name | Committee Name |
|---|---|---|---|---|---|
| April 02, 2025 | House | Floor | Action | Introduction and first reading, referred to | Health Finance and Policy |
Citations
[
{
"analysis": {
"added": [
"Requires reporting of aggregated payments made to contract pharmacies and other entities not part of the covered entity."
],
"removed": [
""
],
"summary": "This bill modifies reporting requirements for 340B covered entities participating in the federal 340B program under section 62J.461, subdivision 3.",
"modified": [
"Enhances detail required for aggregated acquisition costs and payments by payer type."
]
},
"citation": "62J.461",
"subdivision": "subdivision 3"
},
{
"analysis": {
"added": [
"Outlines conditions under which the commissioner may grant reporting extensions or exemptions."
],
"removed": [
""
],
"summary": "This bill updates enforcement provisions and reporting exceptions for health care entities under section 62J.461, subdivision 4.",
"modified": [
"Specifies fine structures for non-compliance with reporting provisions."
]
},
"citation": "62J.461",
"subdivision": "subdivision 4"
},
{
"analysis": {
"added": [
"Details enhanced disclosure of aggregate data for significant 340B net revenue entities."
],
"removed": [
""
],
"summary": "Adjustments to the duty of reporting annual data to the legislature under 62J.461, subdivision 5.",
"modified": [
"Expands the scope of included data to cover revenue calculations."
]
},
"citation": "62J.461",
"subdivision": "subdivision 5"
},
{
"analysis": {
"added": [
"Introduces new definition of 'New prescription drug' and clarifies 'Patient assistance program'."
],
"removed": [
""
],
"summary": "Modifications to definitions relating to prescription drug transparency under section 62J.84, subdivision 2.",
"modified": [
"Refines definitions to align with federal drug terminology."
]
},
"citation": "62J.84",
"subdivision": "subdivision 2"
},
{
"analysis": {
"added": [
"Includes expanded criteria for reporting increase based on calendar year comparisons."
],
"removed": [
""
],
"summary": "Alters reporting requirements for prescription drug price increases under section 62J.84, subdivision 3.",
"modified": [
"Changes the percentage thresholds for reporting price increases."
]
},
"citation": "62J.84",
"subdivision": "subdivision 3"
},
{
"analysis": {
"added": [
"Mandates easy-to-read format for public information on prescription drugs."
],
"removed": [
""
],
"summary": "Updates public posting obligations for drug price information under section 62J.84, subdivision 6.",
"modified": [
"Clarifies withholding criteria for non-public or trade secret data."
]
},
"citation": "62J.84",
"subdivision": "subdivision 6"
},
{
"analysis": {
"added": [
"Initiates quarterly updates of drugs of public interest based on specific cost criteria."
],
"removed": [
""
],
"summary": "Establishes requirements for public interest notice regarding prescription drugs under section 62J.84, subdivision 10.",
"modified": [
"Regulates the maximum number of drugs identified per notice for public interest."
]
},
"citation": "62J.84",
"subdivision": "subdivision 10"
}
]Progress through the legislative process
In Committee